ExploreWatchlistsPricing
  1. US-listed companies
  2. IMMUNIC, INC.
  3. Financials
  4. Stock-based compensation

IMMUNIC, INC. (IMUX)

Market cap
$1.3B
P/E ratio
SummaryFinancials
Period EndStock-based compensation (Million USD)YoY (%)
Dec 31, 20259+3.94%
Dec 31, 20249+20.06%
Dec 31, 20237-10.43%
Dec 31, 20228+33.28%
Dec 31, 20216+116.56%
Dec 31, 20203-57.82%
Dec 31, 20197+74.30%
Dec 31, 20184-31.82%
Dec 31, 20175+17.14%
Dec 31, 20165+16.11%
Dec 31, 20154+60.52%
Dec 31, 20143

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat